Jānis Meikšāns, newly appointed general manager of Teva Hungary, speaks about his first few months in the country. Meikšāns goes on to elaborate on Hungary’s key positioning as a strategic affiliate for Teva with strong R&D and manufacturing operations. Additionally, he highlights Teva’s longstanding commitment to the country not only as a key investor but also a partner to the healthcare system through providing value-added generics in key therapeutic areas such as cardiology.
Just like we had a mission for chemical generics, our future focus will be to build awareness and educate society on biosimilars and the unique value that these products bring.
